Benitec Biopharma Inc. (NASDAQ:BNTC) Receives $19.50 Average Price Target from Analysts

Benitec Biopharma Inc. (NASDAQ:BNTC) has been given a consensus rating of “Buy” by the six analysts that are currently covering the stock, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $22.60.

BNTC has been the topic of a number of recent analyst reports. Oppenheimer initiated coverage on shares of Benitec Biopharma in a research report on Wednesday. They issued an “outperform” rating and a $35.00 target price on the stock. JMP Securities increased their target price on shares of Benitec Biopharma from $16.00 to $18.00 and gave the company a “market outperform” rating in a research report on Monday, October 14th. Leerink Partners initiated coverage on shares of Benitec Biopharma in a research report on Monday, July 22nd. They set an “outperform” rating and a $13.00 price objective on the stock. Leerink Partnrs raised shares of Benitec Biopharma to a “strong-buy” rating in a research report on Monday, July 22nd. Finally, Guggenheim initiated coverage on shares of Benitec Biopharma in a research report on Thursday, September 12th. They set a “buy” rating and a $17.00 price objective on the stock.

Institutional Trading of Benitec Biopharma

Several hedge funds have recently made changes to their positions in the company. GAMMA Investing LLC lifted its stake in shares of Benitec Biopharma by 20.3% in the 3rd quarter. GAMMA Investing LLC now owns 6,540 shares of the biotechnology company’s stock worth $60,000 after acquiring an additional 1,102 shares during the period. Nantahala Capital Management LLC acquired a new stake in shares of Benitec Biopharma in the 2nd quarter worth $5,881,000. Simplify Asset Management Inc. acquired a new stake in shares of Benitec Biopharma in the 2nd quarter worth $358,000. Finally, Janus Henderson Group PLC lifted its stake in shares of Benitec Biopharma by 35.5% in the 1st quarter. Janus Henderson Group PLC now owns 244,491 shares of the biotechnology company’s stock worth $1,266,000 after acquiring an additional 64,092 shares during the period. Institutional investors and hedge funds own 52.19% of the company’s stock.

Benitec Biopharma Price Performance

NASDAQ BNTC opened at $11.48 on Wednesday. The firm’s fifty day moving average price is $9.23 and its 200 day moving average price is $8.40. The company has a market capitalization of $107.54 million, a price-to-earnings ratio of -6.01 and a beta of 0.90. Benitec Biopharma has a 12 month low of $2.69 and a 12 month high of $12.89.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.